|
|
楼主 |
发表于 2024-5-9 10:18:51
|
显示全部楼层
: ], X$ }0 ^$ l% t, I5 E2 D
我看了下，入选今年ASCO的中肿研究，有4项是随机、3期临床试验，2项鼻咽癌+2项肺癌，这4项应该都能发很不错的文章，其余1-2期的应该也有子刊的水平
3 O( t3 `+ b, G2 I* M
0 M1 B) @/ z9 ^. v6 H& D) CIvonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.
* G! S, e/ H7 z: F G4 P" sIvonescimab联合化疗治疗接受EGFR-TKI治疗进展的EGFR突变非鳞状NSCLC患者(HARMONi-A)：一项随机、双盲、多中心、III期试验
# z8 g& C# P! l/ }8 k讲者：张力 中山大学肿瘤防治中心
$ s/ c6 T/ H$ L# g% Q' f& S9 B2 s# Y8 n, T" p3 v* j9 a( H
Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial.
) Q5 W" t7 D9 ~3 ?9 Y. R9 k可切除EGFR突变II-IIIA期NSCLC接受12个月或6个月的埃克替尼辅助治疗对比辅助化疗后观察：一项随机III期试验(ICTAN，GASTO1002)7 d" l2 {8 K! G9 g
讲者：王思愚 中山大学肿瘤防治中心
; g) E. C+ L2 Q* d0 r9 y0 [- U# w
6 M+ K9 V, r# l6 E, b% c5 yTislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial.# r. K6 F7 t1 l# H$ x2 f
替雷利珠单抗对比安慰剂联合诱导化疗序贯同步放化疗，继以替雷利珠单抗或安慰剂辅助治疗局部晚期鼻咽癌：一项多中心、随机、安慰剂对照、双盲、III期试验的期中分析# i8 w2 L" P2 A% ~: I, @* ]
讲者：陈秋燕 中山大学肿瘤防治中心
! F# l- j) P4 X( r% A5 K; ]
$ I; X- K; W) ?/ DAdjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.& W, u; x( z2 n( K* [. Q8 L2 l
卡瑞利珠单抗辅助治疗高危局部晚期鼻咽癌(DIPPER)：一项多中心、开放标签、III期随机对照试验& j' `- W: C8 j0 o
讲者：刘需 中山大学肿瘤防治中心. i1 }0 r3 J$ ^
( Z2 g2 H+ x, m4 U$ m |
|
[复制链接]
发表于 2024-5-9 08:59:18
